Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
The buyer will assume future milestone and royalty obligations after closing, while Exicure retains earlier program liabilities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exicure (XCUR) agreed to sell its GPC-100 program assets to GPCRT for an aggregate cash purchase price of KRW 6.5 billion. The agreement, signed November 4, 2026, values the sale at approximately US$4.8 million. KRW 500 million was previously paid; KRW 2.0 billion is payable by November 16, 2026, and KRW 4.0 billion at closing, unless otherwise agreed in writing.
GPCRT will assume assigned license and contract obligations after closing and bear program costs incurred on or after September 1, 2026. Exicure and GPCR USA retain other liabilities, including earlier program liabilities. Closing requires approvals and third-party consents, a GPCR Therapeutics waiver and release, and any required shareholder approval. GPCR USA remains wholly owned by Exicure.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointGPC-100 asset sale agreement provides for KRW 6.5 billion in cash, approximately US$4.8 million. 82% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.GPCRT will assume future milestone and royalty payments and assigned contract obligations after closing.
- Minor point. Forward-looking: it has not happened yet and may not happen.GPCRT will bear GPC-100 program costs incurred on or after September 1, 2026.
- Minor pointGPCR USA completed its GPC-100 Phase 2 clinical trial in January 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Exicure expects the sale to strengthen its financial position as part of its evaluation of strategic alternatives.
Negative
- Moderate pointExicure and GPCR USA retain all other liabilities, including program liabilities incurred before September 1, 2026.
- Minor pointClosing requires third-party consents and approvals, a GPCR Therapeutics waiver and release, and any required shareholder approval.
Details
Market Reaction – XCUR
On Nov 10, the day this news came out, the latest delayed price for XCUR is 2.78% below the previous close. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner has recorded 23 alerts for this stock so far that day. The latest delayed price is $1.05. Relative volume is exceptionally heavy at 31.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Aggregate cash purchase price
- KRW 6.5 billion
- GPC-100 program assets
- Previously paid
- KRW 500 million
- Credited against the purchase price
- Payment installment
- KRW 2.0 billion
- Payable on or before November 16, 2026, subject to an agreed alternative date
- Closing payment
- KRW 4.0 billion
- Remaining purchase price payable at closing
- Program cost responsibility begins
- September 1, 2026
- GPCRT will bear GPC-100 program costs incurred on or after this date
Historical Context
-
Planned equity issuance settled a $1.0 million Phase 2 milestone under the same license agreement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
intellectual property financial
multiple myeloma medical
stem cell mobilization medical
phase 2 clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company’s GPC-100 (burixafor) program assets for an aggregate cash purchase price of KRW 6.5 billion (approximately US
The assets to be sold consist of the Company’s rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc. dated January 19, 2025, together with the related contracts, intellectual property, clinical and regulatory data, materials and equipment of the Company and GPCR USA used in the GPC-100 program. GPC-100 is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma, and GPCR USA completed its Phase 2 clinical trial of GPC-100 in January 2026. GPCR USA will remain a wholly owned subsidiary of Exicure following the closing.
Of the purchase price, KRW 500 million has previously been paid by GPCRT and will be credited against the purchase price, KRW 2.0 billion is payable on or before November 16, 2026 and the remaining KRW 4.0 billion is payable at the closing, in each case subject to any other payment date agreed by the parties in writing. From and after the closing, GPCRT will assume the obligations under the License and Collaboration Agreement, including future milestone and royalty payments, and under the assigned program contracts, and GPCRT will bear the costs of the GPC-100 program incurred on or after September 1, 2026, as provided in the Agreement. Exicure and GPCR USA will retain all other liabilities, including GPC-100 program liabilities incurred before September 1, 2026.
The closing is subject to customary closing conditions, including required approvals and third-party consents, a waiver and release from GPCR Therapeutics, Inc. and any approval of the Company’s stockholders that may be required. There can be no assurance that the transaction will be completed on the anticipated timetable or at all.
The sale of the GPC-100 program assets is part of the Company’s ongoing evaluation of strategic alternatives intended to maximize stockholder value and is expected to strengthen the Company’s financial position.
Additional information regarding the Agreement is included in the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”).
About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and the suspension of its clinical and development activities, the Company has been evaluating strategic alternatives to maximize stockholder value. In January 2025, the Company acquired GPCR Therapeutics USA Inc., a clinical-stage biotechnology company developing treatments for blood disorders, whose lead program, GPC-100, has been evaluated for improving stem cell mobilization in multiple myeloma and sickle cell disease and for supporting cell and gene therapy. For more information, visit www.exicuretx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the proposed sale of the GPC-100 program assets, the expected timing of the interim payment and the closing, the satisfaction of closing conditions, the assumption of liabilities and the reimbursement of costs by GPCRT, the expected effect of the transaction on the Company’s financial position, and the Company’s evaluation of strategic alternatives, are forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “will,” “may” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that the closing conditions are not satisfied or waived, that required consents, waivers or approvals are not obtained, that GPCRT does not make the payments when due, that the parties modify the terms or structure of the transaction, that the Company may have limited or no operating business following the transaction, fluctuations in the exchange rate between the Korean won and the U.S. dollar, the Company’s liquidity and ability to continue as a going concern, and the Company's ability to maintain the listing of its common stock on Nasdaq, as well as the risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update them except as required by law.
Contact
Exicure, Inc.
Email: pr@exicuretx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much will Exicure receive for the GPC-100 assets, and when are payments due?
The aggregate cash purchase price is KRW 6.5 billion, approximately US$4.8 million. GPCRT previously paid KRW 500 million, which will be credited against the price. KRW 2.0 billion is payable on or before November 16, 2026, and KRW 4.0 billion at closing, subject to other payment dates agreed in writing.
What GPC-100 assets is Exicure selling to GPCRT?
The sale covers rights under the January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, together with related contracts, intellectual property, clinical and regulatory data, materials and equipment used in the GPC-100 program. GPC-100 is being evaluated with propranolol for stem cell mobilization in patients with multiple myeloma.